Agreement signedPublished 14 Oct 2026

Galderma /
ZO Skin Health

Galderma agrees to buy Blackstone-backed ZO Skin Health

Buy side: Galderma
Buy sideGalderma
Target: ZO Skin Health
TargetZO Skin Health
Galderma · 14 Oct 2026Source
Buy side: Galderma
Buy sideGalderma
Target: ZO Skin Health
TargetZO Skin Health
01 / BuyerGalderma
02 / SellerBlackstone Tactical Opportunities
03 / TargetZO Skin Health
Source for the buyer, seller and target: Galderma

For the buyer, seller and target.

buyer and target

“Galderma will acquire 100% of ZO Skin Health for an enterprise value of 1.5 billion USD in an all-cash transaction, subject to customary adjustments, and will be funded through a combination of existing cash reserves and bank financing.”

seller

“Zug, Switzerland and Irvine, California – October 14, 2026 – Galderma (SIX: GALD) today announced that it has signed an agreement to acquire ZO ® Skin Health, a leading physician-dispensed skincare brand built on clinical science and protocol-based daily care, from its shareholders, including funds managed by Blackstone Tactical Opportunities (“Blackstone”) and the Obagi family.”

Published 14 Oct 2026

Open the source
01

What happened

Galderma signed an agreement to buy ZO Skin Health, the Irvine, California physician-dispensed skincare brand founded by dermatologist Dr. Zein Obagi, from shareholders that include funds managed by Blackstone Tactical Opportunities and the Obagi family. [01]

The all-cash deal values ZO Skin Health at an enterprise value of 1.5 billion USD, and Galderma expects it to close in the fourth quarter of 2026 or early 2027, pending regulatory approvals. ZO Skin Health had net sales of about 330 million USD in the twelve months to June 2026. [01]

02

The source

Everything on this page comes from the source below, quoted word for word.

01
Source · Galderma

Galderma agrees to buy Blackstone-backed ZO Skin Health

This document is the source for the companies, stage and people on this page.

Open the source
03

Timeline

Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.

  1. Expected close

    “The all-cash deal values ZO Skin Health at an enterprise value of 1.5 billion USD, and Galderma expects it to close in the fourth quarter of 2026 or early 2027, pending regulatory approvals”

    Open the source
  2. Published by Galderma

    The source this page is built from.

    Open the source

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Get ProAlready a member? Sign in

Pro is open to everyone.